Related Experiment Video
Updated: Jul 28, 2025
12:09
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
Published on: February 28, 2019
9.8K
Human soluble CD39 displays substrate inhibition in a substrate-specific manner
Venkat M K Vadlamani1, Kavinda K J Gunasinghe2, Xavier W Chee2
1Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, UK.
Scientific Reports
|June 2, 2023
Summary
CD39 (ectonucleoside triphosphate diphosphohydrolase-1) exhibits substrate inhibition with ADP and ATP, meaning its activity decreases at high concentrations. This finding is crucial for understanding purinergic signaling and developing CD39-targeted therapies.
Area of Science:
- Biochemistry
- Enzymology
- Molecular Biology
Background:
- CD39 (ectonucleoside triphosphate diphosphohydrolase-1) is a key enzyme regulating extracellular purinergic signaling.
- Its activity impacts crucial biological processes including cancer, thrombosis, and autoimmune diseases.
Purpose of the Study:
- To investigate substrate inhibition kinetics of CD39 (ENTPD1) with various nucleotide substrates.
- To elucidate the molecular mechanisms underlying substrate inhibition in CD39 activity.
Main Methods:
- Enzymatic assays using soluble, recombinant CD39 with varying concentrations of ADP, ATP, UDP, UTP, and 2-methylthio-ADP.
- Molecular dynamics simulations to analyze enzyme-substrate interactions within the CD39 active site.
Main Results:
- Soluble CD39 demonstrates significant substrate inhibition with ADP and ATP, but not with UDP or UTP.
- Substrate inhibition is dependent on the nucleotide base, with 2-methylthio-ADP showing no inhibition.
- Molecular dynamics simulations revealed distinct conformational changes of ADP within the CD39 active site.
Conclusions:
- Substrate inhibition is a critical characteristic of CD39 (ENTPD1) activity when using ADP or ATP.
- Understanding this inhibition is essential for accurate interpretation of CD39-related research and drug development targeting purinergic signaling.
Related Concept Videos
01:30Enzyme Inhibition
78.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.8K
00:46Feedback Inhibition
54.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.1K
01:30The Electron Transport Chain
17.0K
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
17.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K